http://rdf.ncbi.nlm.nih.gov/pubchem/reference/27522568

Outgoing Links

Predicate Object
contentType Clinical Trial, Phase II|Journal Article|Research Support, N.I.H., Extramural
endingPage 101
issn 1556-0864
issueIdentifier 1
pageRange 97-101
publicationName Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
startingPage 97
hasFundingAgency http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_3a5b4c37507cfda8bbcc7e7e7401e0bc
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_c555575fa093df37f6b1e9b9e668d30c
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_15e5e73af61abdd2a4bf8fb80caeb4fe
bibliographicCitation Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M, Espinoza-Delgado I, Gandara D. Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma. Journal of Thoracic Oncology. 2009 Jan;4(1):97–101. doi: 10.1097/jto.0b013e318191520c.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_087a1ccdd65a35406cc5b0951fda2a20
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8216eaf0a2fe9de9dab84ef31d462818
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_23d3f7680ffa3195f63071359d059b52
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0ae51189883ef77edc627279dd6e9436
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2d8e0dd4da50802b9fa5db326817a4c3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6e37e77eb1be288f5dce72d26db0560c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ee543f2784b89b772b7cff0ccab8cc3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f77e499ba492d4ae4b0b41f28b87a073
date 200901
identifier https://doi.org/10.1097/jto.0b013e318191520c
https://pubmed.ncbi.nlm.nih.gov/19096314
https://pubmed.ncbi.nlm.nih.gov/PMC3263397
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/33311
https://portal.issn.org/resource/ISSN/1556-0864
language English
source https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
discusses http://id.nlm.nih.gov/mesh/M0010739
http://id.nlm.nih.gov/mesh/M0519759
http://id.nlm.nih.gov/mesh/M0020790
http://id.nlm.nih.gov/mesh/M0527853
http://id.nlm.nih.gov/mesh/M0007520
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D006877Q000627
http://id.nlm.nih.gov/mesh/D016066Q000188
http://id.nlm.nih.gov/mesh/D016879
http://id.nlm.nih.gov/mesh/D008654Q000188
http://id.nlm.nih.gov/mesh/D056572
http://id.nlm.nih.gov/mesh/D004791Q000627
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000369
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D015996
http://id.nlm.nih.gov/mesh/D008654Q000473
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D012074
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D016896
http://id.nlm.nih.gov/mesh/D016066Q000473
http://id.nlm.nih.gov/mesh/D019008
http://id.nlm.nih.gov/mesh/D018572
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D013449
http://id.nlm.nih.gov/mesh/D000328
http://id.nlm.nih.gov/mesh/D020714
http://id.nlm.nih.gov/mesh/D009364Q000175
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8593
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9614
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7333
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID53437714
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8482
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6918638
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.5.1.98
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7706
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6761
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID6956
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID247375212

Total number of triples: 70.